Ardelyx Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Ardelyx (ARDX) Prices 7.5M Common Stock Offering at $10/Share
January 8, 2016 6:47 AM ESTArdelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, for gross proceeds of $75,000,000. In addition, the Company has granted the underwriters of the offering the right for a period of 30 days to... More
